Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Verducatib and Itraconazole in Healthy Men
NCT03890887Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of verducatib in bronchiectasis, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of BI 1291583 in plasma over the time interval from 0 to the last quantifiable data point up to 263 hours and Maximum measured concentration of BI 1291583 in plasma up to 263 hours. Started Apr 2019; status: completed.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT03890887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03890887.